För Sverige i framtiden
Bio-objektifiering av ny medicinsk teknologi
DOI:
https://doi.org/10.37062/sf.50.18366Nyckelord:
Bio-technology, policy, stem cells, xeno transplantation, cybrid, discourse analysis, bio-object, bio-identityAbstract
Taking Sweden into the future – Bio-objectification of new medical technology
In this article, we analyze how contemporary discursive silences around new biotechnologies such as cybrids and induced pluripotent stem cells (iPSC), have been enabled by earlier policy processes in the area, e.g. boundary work around what is human and non-human, living and non-living, subject and object. The analysis of policy processes around xenotransplantations and the use of human embryonic stem cells, shows that the stem cells’ and xenografts’ “bio-identities” become stabilized through high expectations for the future, a lack of therapeutic possibilities and struggles over definitions of life. The policy processes around human embryonic stem cells and organs from other animals, are characterized by a normalization of certain understandings of ”life”, trust in scientific progress and it’s national financial potentials and a categorization of criticism as irrational. Through these “bio-objectification processes”, debate and decision making has been moved from a political and public context into ethical committees and research funding bodies. The article concludes by discussing consequences of this political non-handling of biomedical technologies and how these bioobjects could be re-politicized.
Downloads
Publicerad
Referera så här
Nummer
Sektion
Licens
Allt material i Sociologisk Forskning publiceras med omedelbar öppen tillgång (open access), under Creative Commons-licensen CC BY-NC-ND 4.0.
Allt innehåll i tidskriften är fritt tillgängligt utan kostnad och får för icke-kommersiella syften fritt läsas, laddas ned, kopieras, delas, skrivas ut och länkas. Innehållet får dock inte ändras. När innehållet används måste författare och källa anges. Upphovsrätten till innehållet tillhör respektive författare. Inga publiceringsavgifter tas ut.